By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BioMarin Pharmaceutical Inc. 

105 Digital Drive

Novato  California  94949  U.S.A.
Phone: 415-506-6700 Fax: 415-382-7427


BioMarin leads the biotechnology industry in delivering therapies for chronic and degenerative genetic conditions that reduce patients' quality of life and shorten life spans. We target diseases that lack effective therapies and affect relatively small numbers of patients, many of whom are children. BioMarin continues to focus on advancing therapies that are the first or best of their kind and make a big difference in improving patients' lives.

BioMarin offers a friendly, fast-paced, collegial environment where success is measured by both the individual and collective efforts of hundreds of talented scientists, business professionals, technical specialists and experts in a variety of fields from sales and marketing, to finance, to manufacturing, to clinical and regulatory operations.

BioMarin is growing rapidly to support the development and global commercialization of breakthrough drugs to treat rare genetic diseases. The company’s product portfolio comprises five approved products and multiple clinical and pre-clinical product candidates.

You can make it happen at BioMarin, where the unique combination of big-company success in a small-company environment provides unparalleled opportunity for individual contributions and growth.

Key Statistics

Ownership: Public

Web Site: BioMarin
Employees: 358
Symbol: BMRN

Company News
BioMarin (BMRN) Announces Acceptance Of Late Breaking Abstract At The International Society On Thrombosis And Haemostasis 2017 Congress 6/16/2017 8:40:43 AM
Life Sciences Professionals Name Top 30 Ideal Employers 6/15/2017 10:43:10 AM
CD Access To Provide Special Access Program For Duchenne Muscular Dystrophy Patients In Canada 6/1/2017 8:19:31 AM
BioMarin (BMRN) Release: European Commission (EC) Approves Brineura (Cerliponase Alfa), The First Treatment For CLN2 Disease, A Form Of Batten Disease And Ultra-Rare Brain Disorder In Children 6/1/2017 6:59:47 AM
BioMarin (BMRN) Announces First Quarter 2017 Financial Results 5/5/2017 8:42:22 AM
Wowsers! FDA Approves BioMarin (BMRN)'s Brineura, the First Drug for Batten Disease 4/28/2017 5:39:06 AM
BioMarin (BMRN) Receives Positive CHMP Opinion In Europe For Brineura (Cerliponase Alfa) For First Treatment Of CLN2 Disease, A Form Of Batten Disease And Ultra-Rare And Fatal Brain Disorder In Children 4/24/2017 7:41:19 AM
BioMarin (BMRN) To Host First Quarter 2017 Financial Results Conference Call And Webcast On Thursday, May 4 At 4:30pm ET 4/21/2017 7:31:01 AM
BioMarin (BMRN) Announces Kuvan (sapropterin dihydrochloride) Patent Challenge Settlement 4/13/2017 9:05:17 AM
BioMarin (BMRN) Announces Fourth Quarter And Full Year 2016 Financial Results 2/24/2017 6:58:03 AM